Our fermentation capacity map was an exercise in tracking who is building tanks and how far behind schedule they are. The mycoprotein producers we looked at yesterday mostly solved the problem by building next to a sugar mill. Believer Meats solved it by spending roughly $154m on a plant it never ran at scale.
Superbrewed Food took the third route, and in February 2026 it produced a result: ingredients group Döhler is now manufacturing SB1 commercially in Europe — fermentation at a Döhler facility in the Netherlands, followed by spray drying in Germany — with Döhler Ventures taking an undisclosed equity stake in Superbrewed at the same time.
The interesting part of this is not the announcement. It is what founder and CEO Dr Bryan Tracy said about why most versions of this arrangement do not work.
What was actually transferred
The phrase doing the work in the release is “commercial production”, and it is worth being precise about what that covers, because two separate unit operations at two sites in two countries had to be qualified.
Tracy’s own framing draws the distinction sharply:
“We have done the full tech transfer into Döhler’s facility [in the Netherlands, followed by spray drying in Germany] and now produce reliable, reproducible, high quality, hygienic products.”
Against, in his account, what much of the sector is announcing:
“You’re seeing CMO deals being signed everywhere right now that are giving investors the impression that people don’t need to invest capital to expand their production with all the risk going to the CMO, and that’s not realistic.”
He then names four specific failure modes, and this is the most operationally useful paragraph published on contract fermentation this year:
- Drying is frequently not on site. “Some of these facilities don’t have drying capacity on site, so you have to take it off site to get it dried.” Superbrewed’s own arrangement is an instance of exactly this — Netherlands to Germany — which is why the hygiene question below is not hypothetical.
- Hygiene across that transfer is unsolved by default. “Have they ever dealt with the hygiene challenges associated with that in a real industrial setting?”
- The capex does not disappear, it moves. “All these startups are very different from each other with bespoke needs that may require a substantial capex investment into your contract manufacturing partner.” A CMO deal is not a capex-free scale-up; it is capex spent in someone else’s building, on someone else’s schedule.
- You will not find a clean fit. “You’re not going to find a facility that has every last piece of equipment that you need. Maybe they have microfiltration capabilities, but not the exact type you’ll need.” Plus “complexity in shoehorning it into somebody else’s facility that’s trying to do three other things.”
That fourth point is the one the capacity map kept running into from the other direction. Available tank volume is not the same as available capacity, because a tank is attached to a downstream train — separation, drying, packing — that was specified for a different product.
The ingredient
SB1 is not a precision-fermented protein and should not be filed alongside one.
Superbrewed grows a non-GMO bacterium that naturally produces high protein levels when grown anaerobically on sugars from a variety of feedstocks, then harvests the whole biomass. There is no target protein being expressed and purified out. The organism is deactivated — “the bacteria are not ‘live’”, per Tracy — and the resulting powder is sold as an ingredient in its own right.
That distinction has a direct economic consequence that Tracy points out. Precision fermentation companies “are left with large amounts of microbial biomass at the end of each batch that is either thrown away or sent to the animal feed market”. Here the biomass is the product, and there is a co-product, butyric acid, with an established market.
The stated specification, per AgFunderNews:
| Attribute | Stated value |
|---|---|
| Protein content | 88%+ |
| Organism | Non-GMO bacterium, anaerobic growth, fully deactivated |
| US label declaration | “postbiotic cultured protein” |
| Sensory | Neutral taste and colour |
| Functional | Strong pH and heat stability, good emulsification |
| Micronutrients | Meaningful levels of B vitamins, iron and zinc |
| US regulatory | FDA GRAS “no questions” letter, 2024 |
Superbrewed announced in March 2024 that it was the first company to receive a US FDA no-questions letter for a bacteria biomass protein, distinguishing it from the fungal biomass proteins that had gone before. Set against our running count of US clearances, this sits in a different lane: a whole-organism biomass ingredient rather than a single expressed protein.
Tracy also cites third-party academic work “across allergenicity, nutritional quality vs. whey protein isolate for muscle protein synthesis via human clinical trials, and functionality, from studies at Maastricht, Utrecht, and Wageningen universities” — with results presented at NUTRITION 2026 reported as showing the protein matching whey in muscle-building response. We have not read those papers and are reporting the claim, not endorsing it.
The formulation claim worth testing
The most checkable technical claim Superbrewed makes is about solubility and viscosity at high protein loading, which is the actual constraint in the protein-beverage category it is selling into.
“Let’s say you wanted to get as much as 35g of fully digestible protein into a beverage, even with dairy products, you’re going to need 12oz [of liquid]. In the plant-based world, you’re going to need 16oz, because it gets really viscous. With SB1, you could put 35g of protein in five ounces of water and the texture would still be very nice.”
Reduced to numbers, that is a claimed loading of roughly 35g of protein in 148ml — call it 24% w/v — against 12oz (355ml, ~10%) for dairy and 16oz (473ml, ~7%) for plant protein. If it holds, it is the difference between a shot format and a bottle format, which is a packaging and logistics decision, not a taste one.
It is also, notably, a claim about a finished-format constraint rather than about protein content — the kind of specification a beverage developer can actually design against. We have not seen the underlying rheology data, and Tracy gives no shear or temperature conditions with those figures.
On price he is deliberately vague: “Highly functional dairy protein ingredients are only increasing in price, and we’re already at a pretty competitive price point with similar functionality and nutritional density.” No figure, no basis, no reference product. That is the same gap we find on almost every cost claim in this sector, and it is worth saying that an ingredient which has genuinely reached commercial production is now one of the few in a position to disclose a real number.
What this does and does not solve
Döhler Ventures’ managing partner Rodrigo Hortega de Velasco frames the investment as supporting SB1 “as it scales globally”. Tracy is more measured about where that leaves Superbrewed: the company is “assembling financing to repurpose a larger anaerobic fermentation facility in the US”, and initial commercial volumes are shipping into premium sports and lifestyle nutrition in the US, with broader commercialisation targeted for 2027.
So the honest position is this. Superbrewed has solved the qualification problem, not the volume problem. It has a validated, transferred, reproducible process in an industrial plant — which is materially more than most of the sector can say, and which is the step that usually takes years and kills companies. What it has not got is capacity it controls. Its 2026 output is whatever Döhler chooses to allocate to it against a plant that, by Tracy’s own description of the category, is “trying to do three other things”.
Repurposing an existing anaerobic facility is a real strategy — it is the same instinct as building next to a sugar mill, or Millow taking over an old LEGO hall — but it is unfunded as of the February 2026 reporting.
The counter-argument
A partner-led model trades a capital problem for a control problem, and that is not obviously the better trade. Believer Meats owned its plant and still failed, so ownership plainly is not sufficient. But it is also true that a company without capacity of its own cannot commit to an offtake agreement on its own authority, cannot unilaterally schedule a campaign, and cannot easily improve its own unit economics, because the cost structure belongs to somebody else’s balance sheet. Every efficiency gain has to be negotiated.
And Tracy’s critique cuts at his own arrangement too. He identifies off-site drying as a red flag and then describes a process that ferments in one country and dries in another. His defence is that Superbrewed did the transfer properly rather than on paper — but “we did it properly” is not independently verifiable from a press release, and the specific hygiene risk he raises is one his own configuration carries.
Third, the equity investment complicates the reading. Döhler is simultaneously the manufacturer and a shareholder. That alignment is genuinely useful for getting capex approved inside Döhler’s plant, and it also means the commercial terms of the manufacturing agreement are not arm’s-length in the way a straightforward CMO contract would be. Neither party has disclosed those terms.
What we could not establish
- No GRN number. The FDA GRAS notice link cited in AgFunderNews’s report
(
fda.gov/media/185891) now returns a 404, and we could not identify the GRN inventory number for Superbrewed’s postbiotic cultured protein from any source we checked. We have cited the company’s own March 2024 announcement of the no-questions letter instead, and flag that we have not read the letter. - Protein content is stated two ways. AgFunderNews reports “88%+ protein”; the PR Newswire release and other coverage say “over 85% protein”. Both may be true of different lots or specifications; we have used 88%+ where attributing to AgFunderNews and noted the discrepancy here rather than silently picking one.
- No tonnage. Neither party has disclosed the capacity allocated at the Döhler site, the batch size, or the annual volume SB1 can currently reach. “Commercial production” is not a quantity.
- No price, and no basis. See above.
- The Döhler Ventures investment is undisclosed, so the depth of the alignment cannot be assessed.
- We have not read the Maastricht, Utrecht or Wageningen studies, nor the NUTRITION 2026 presentation. The muscle-protein-synthesis parity claim against whey isolate is reported, not verified.
- The US facility is unnamed and unfunded as of the reporting we have. We do not know whether it is a site Superbrewed has identified and is negotiating for, or a category of site it intends to find.
What to watch
- Whether a tonnage figure ever appears. Until one does, “commercial production” cannot be compared with any other producer’s output, and the ingredient’s real availability to a formulator is unknown.
- Whether the US anaerobic facility gets financed. Tracy says financing is being assembled. That is the step that converts a qualified process into controlled capacity.
- Whether Döhler expands the allocation in 2027. Both parties named 2027 as the year for broader commercialisation. Watch whether that arrives as more volume at the same site or as a second site.
- Whether anyone else copies the drying split. If a fermentation-in-one-country, drying-in-another arrangement can be qualified reliably, it widens the set of usable contract facilities considerably — which would matter more to the sector than SB1 itself does.
- Whether the price gets published. An ingredient in industrial production with a competitive-price claim and no number attached is the cost data gap in miniature.